Patent cliffs & loss of exclusivity
Trevena is a biopharmaceutical company developing medicines for central nervous system disorders. Its pipeline includes investigational TRV045, TRV250 and TRV734. Its FDA-approved acute-pain medicine OLINVYK (oliceridine) had U.S. commercial sales discontinued effective December31,2024. The company began operations in2007 and adopted the Trevena name in2008; it remains under restructuring with consulting officers.
| AngelList URL | https://angel.co/trevena |
|---|---|
| CAGE Code | 5BXZ4 |
| Legal Name | Trevena, Inc. |
| Company Operating Status | Active |
| Contact Page URL | https://www.trevena.com/contact |
| Crunchbase URL | https://www.crunchbase.com/organization/trevena |
| Full Address | 955 Chesterbrook Blvd, Suite 110, Chesterbrook, Pennsylvania 19087, US |
| LinkedIn URL | http://www.linkedin.com/company/trevena-inc |
Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.